Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:27 2024-04-23 am EDT			Pre-market 02:00:17 am
2.42 ^EUR	-1.43%		2.35	-2.89%

Apr. 22	Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	CI
Apr. 22	European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	MT

Cellectis S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 03, 2022 at 05:09 pm EDT

Cellectis S.A. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.217 million compared to USD 8.31 million a year ago. Revenue was USD 1.92 million compared to USD 10.83 million a year ago. Net loss was USD 28.47 million compared to USD 37.41 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 0.63 compared to USD 0.82 a year ago.
For the nine months, sales was USD 3.26 million compared to USD 45.09 million a year ago. Revenue was USD 8.52 million compared to USD 53.41 million a year ago. Net loss was USD 79.33 million compared to USD 89.2 million a year ago. Basic loss per share from continuing operations was USD 1.74 compared to USD 2 a year ago. Diluted loss per share from continuing operations was USD 1.74 compared to USD 2 a year ago.

Latest news about Cellectis S.A.

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs	Apr. 22	CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 11	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 28	MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	Feb. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	Feb. 23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Feb. 13	MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading	Feb. 12	MT
AstraZeneca: $300 million invested in the USA	Feb. 06	CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Trading	Jan. 29	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%	Jan. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Jan. 17	MT
Cellectis: second tranche of EIB loan drawn down	Jan. 17	CF
Cellectis Draws Down EUR15 Million Tranche Under European Investment Bank Credit Facility	Jan. 17	MT
Cellectis Announces the Drawdown of the Second Tranche of 15 Million Under the Credit Facility Agreement Entered with the European Investment Bank	Jan. 16	CI

Chart Cellectis S.A.

Duration

Period

More charts

Company Profile

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.

Sector

Biotechnology & Medical Research

Calendar

05:15am - The CRISPR MEDiCiNE Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Cellectis S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLECTIS S.A.	-12.45%	186M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.83%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research